601607 Shanghai Pharmaceuticals Holding
- 18.46
- 0.000.00%
Shanghai Pharmaceuticals Holding News
Express News | Shanghai Pharmaceutical: Metoclopramide hydrochloride injection passed generic drug consistency evaluation
Express News | Shanghai Pharmaceutical: Sacubatl Valsartan Sodium Tablets Approved for Production
Changes in Hong Kong stocks | Shanghai Pharmaceutical (02607) rose more than 5% in the afternoon, I031 tablets approved for clinical trials, approved for production of injectable methotrexate
Shanghai Pharmaceutical (02607) rose more than 5% in the afternoon. As of press release, it rose 4.26% to HK$12.72, with a turnover of HK$76.06 million.
Shanghai Pharmaceuticals Gets Regulatory Nod to Trial Tumor Drug
Shanghai Pharmaceuticals Holding (SHA:601607, HKG:2607) will conduct clinical trials on the I031 tablets after receiving approval from China's National Medical Products Administration, the company sai
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
Shanghai Pharmaceutical (601607.SH): I031 tablets approved for clinical trials, which can inhibit tumor proliferation
Zhitong Finance App News, Shanghai Pharmaceutical (601607.SH) announced that recently, the “I031 tablets” independently developed by the company received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (“State Drug Administration”). According to reports, I031 is a small molecule inhibitor that can inhibit tumor proliferation. Preclinical studies have shown that I031 can inhibit tumor growth in animal models of human tumors.
Express News | Shanghai Pharmaceutical: Clinical trial approval notice obtained on I031
Express News | Shanghai Pharmaceutical: Injection methotrexate approved for production
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
A subsidiary of Novizan (688105.SH) and a subsidiary of Shanghai Pharmaceutical reached a cooperation on businesses such as Alzheimer's disease blood test products
Novi Zan (688105.SH) announced that Nanjing Novi Zan Medical Technology Co., Ltd., a wholly-owned subsidiary of the company (“Novi...
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Express News | Shanghai Pharmaceuticals: Levosimendan injection approved for production
Shanghai Pharmaceutical (601607): Steady growth in performance is optimistic about improving operations throughout the year
Core view On April 26, the company released the first quarter results report of 2024, achieving operating income of 70.153 billion yuan, an increase of 5.93% over the previous year, and a net profit of 1,542 billion yuan, an increase of 1.6 billion yuan over the previous year
Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of three R&D projects including the I010 project
Shanghai Pharmaceutical (601607.SH): New specifications for injectable parecoxib sodium have been approved
Gelonghui, April 30 | Shanghai Pharmaceutical (601607.SH) announced that its wholly-owned subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical Co., Ltd., received the “Drug Supplement Application Approval Notice” issued by the State Drug Administration, and the new specification of the drug, 40 mg, was approved. Injectable parecoxib sodium is mainly used for short-term treatment of pain after surgery. It was first developed by Pfizer and marketed in Europe in 2002.
Express News | Shanghai Pharmaceutical: Terminating clinical trials and subsequent development of the I010, B002 and B003 projects
Shanghai Pharmaceuticals Holding's Q1 Profit Rises 2% as Revenue Grows 6%
Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) attributable profit rose 1.62% year over year to 1.54 billion yuan in the first quarter from 1.52 billion yuan, according to separate filings
Featured announcements | The total amount of AIA share repurchase plans increased to US$12 billion; Sinopec's net profit for the first quarter decreased 8.9% year-on-year
China Shenhua's net profit for the first quarter was 15.884 billion yuan, a year-on-year decrease of 14.7%; China Life Insurance's net profit for the first quarter was 20.644 billion yuan, a decrease of 9.3% year-on-year.
Express News | Shanghai Pharmaceutical: It is intended to issue various short-term debt financing products and medium- to long-term debt financing products with a balance equal to RMB 15 billion.
Shanghai Pharmaceutical (02607) plans to apply for the issuance of various short-term debt financing products and medium- to long-term debt financing products
Shanghai Pharmaceutical (02607) issued an announcement. The company plans to apply for a distribution balance of not more than RMB 15 billion worth of all types...
Analysis
Price Target
No Data
